CHME
China Medicine Corporation, through its subsidiary, Guangzhou Konzern Medicine Co., Ltd., engages in the research, development, and distribution of various pharmaceutical and nutritional supplement products in China. It sells approximately 1,100 medicine products, including, traditional Chinese medicine (finished medicine made of Chinese herbs), Chinese herbs, and nutritional supplements, which include both prescription and non prescription drugs. China Medicine Corporation's sales network reaches 28 provinces, approximately 300 hospitals, 500 medicine companies, and 1788 drug stores throughout China. CHME went public on December 1, 2006.
Share Price: = $3.65
EPS (ttm): = $0.55
PE: = 6.6
PEG Ratio: = .22 (Estimated 30% Growth)
Price/Sales: = 1.47
Profitability:
Profit Margin (ttm): 21.72%
Operating Margin (ttm): 31.50%
Management Effectiveness:
Return on Assets (ttm): 41.58%
Return on Equity (ttm): 54.46%
Shares Outstanding = 7.38 Million
